Skip to main content
. Author manuscript; available in PMC: 2010 Apr 7.
Published in final edited form as: J Am Coll Cardiol. 2009 Apr 7;53(14):1204–1210. doi: 10.1016/j.jacc.2008.12.032

Table 1.

Comparison of CMR Findings Between Control and DMD Groups

Patient Groups Parameters A ( n = 16) B (n = 16) C (n = 31) D (n =12) E (n = 11)
Age (years) 14.5±8.4* 8.4±0.84* 13.0±2.9* 15.8±4.5 17.3±5.3
Heart Rate (bpm) 81±15* 106±15 101±16 103±6 112±19
LVM/BSAZ −2.0±1.2 −2.0±0.76* −1.5±0.60 −0.88±1.7* 0.46±1.1
LVEDV/BSAZ −2.0±0.96 −1.6±0.70 −2.1±1.4 −0.20±3.9 2.6±3.8
EDMass/LHT2.7 18.5±6.3* 25.8±5.0 26.7±4.2 28.8±9.2* 37±10
EF (%) 65.1±3.7 65.5±3.7 64.1±5.5* 47.4±7.4* 32.7±14.9
εcc (%) −18.6±2.0* −14.4±1.1* −12.4±2.1* −10±1.9* −6.5±1.2
MDE Performed 0/16 7/16 26/31 10/12 11/11
MDE Result --------------- Negative Negative Negative Negative

Abbreviations: BPM = beat per minute, CMR = Cardiac Magnetic Resonance Imaging, DMD = Duchenne Muscular Dystrophy, ECG = Electrocardiogram, εcc = Circumferential Strain, EDMass/HT2.7 = Left Ventricular Endiastolic Mass ÷ height2.7, EF = Ejection Fraction, Group A = Control, Group B = DMD age ≤10, Group C = DMD age >10 Normal EF and MDE negative, Group D = DMD age >10 Reduced EF and MDE negative, Group E = DMD age >10 Reduced EF and MDE positive, LVM/BSAZ = Left Ventricular Mass Z-score adjusted to Body Surface Area, LVEDV/BSAZ = Left Ventricular Endiastolic Volume Z-score adjusted to Body Surface Area, MDE = Myocardial Delayed Enhancement, n = Number of patient in each group

*

P value (<0.05) is significant compared to the preceding group.

HHS Vulnerability Disclosure